5

10

15

## **CLAIMS**

- 1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4.
- 2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4.
- 3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4.
- 4. An isolated polypeptide of SEQ ID NO:2 and SEQ ID NO:4.
- 5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:2 or SEQ ID NO:4.
- 6. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2,4 over the entire length of SEQ ID NO:2,4; or a nucleotide sequence complementary to said isolated polynucleotide.
- 7. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2,4 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

10

25


- 8. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1,3 over the entire length of SEQ ID NO:1,3 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.
- 9. The isolated polynucleotide as claimed in any one of claims 6 to 8 in which the identity is at least 95% to SEQ ID NO:1,3.
  - 10. An isolated polynucleotide comprising a nucleotide seguence encoding the polypeptide of SEQ ID NO:2 and SEQ ID NO:4.
  - 11. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1 and SEQ ID NO:3.
- 12. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide
  of SEQ ID NO:2 and SEQ ID NO:4, obtainable by screening an appropriate library under
  stringent hybridization conditions with a labeled probe having the sequence of SEQ ID
  NO:1 and SEQ ID NO:3 or a tragment thereof.
- 13. An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 6 12.
  - 14. A host cell comprising the expression vector of claim 13 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4.
  - 15. A process for producing a polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4 comprising culturing a host cell of claim 14 under conditions

20

25

sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

- 16. A process for expressing a polynucleotide of any one of claims 6 12 comprising
   transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.
- 17. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 5 and a pharmaceutically acceptable carrier.
  - 18. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 6 to 12 and a pharmaceutically acceptable carrier.
- 15 19. The vaccine composition according to either one of claims 17 or 18 wherein said composition comprises at least one other *Neisseria meningitidis* antigen.
  - 20. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 5.
  - 21. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 5, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection.
  - 22. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1-5 in the preparation of a medicament for use in generating an immune response in an animal.



5 24. A therapeutic composition useful in treating humans with *Neisseria meningitidis* disease comprising at least one antibody directed against the polypeptide of claims 1 – 5 and a suitable pharmaceutical carrier.

